EDECMO Podcast

Zack Shinar, MD

The ED ECMO Project is the work of Zack Shinar and Jon Marinaro to bring extracorporeal life support to EDs and ICUs around the world. This site aims to be the ultimate resource for the background, logistics, and evidence for resuscitative ECMO.

  1. 1D AGO

    EDECMO 103: HIV and ECMO

    Critical Care ECMO with Dr. Jon Marinaro, Dr. Gary Schwartz and Dr. Cedrick Spak –   Episode 103 Key Points: ECMO in HIV/AIDS Patients 1. HIV Is No Longer a Strong Contraindication to ECMO Historically, HIV and severe immunosuppression were considered relative contraindications for ECMO. With modern antiretroviral therapy (ART), outcomes have dramatically improved. Patients with HIV who receive effective ART can recover immune function and achieve near-normal life expectancy. Therefore, HIV alone should not exclude patients from ECMO candidacy. 2. Immune Reconstitution Makes Recovery Possible ART can rapidly suppress viral load and restore immune function. Patients with very low CD4 counts (even 800) over time. This means even severely immunocompromised patients may recover if given time and support. ECMO can act as a bridge to immune recovery. 3. ECMO Functions as a “Pause Button” ECMO stabilizes respiratory or cardiac failure while clinicians: Treat infections Start ART Manage complications This buys time for reversible disease processes to recover. 4. Major Cause of Respiratory Failure: Pneumocystis Pneumonia Common features in HIV patients requiring ECMO: Pneumocystis jirovecii pneumonia (PJP) Severe respiratory failure Cystic lung destruction Frequent bronchopleural fistulas and pneumothorax Ventilation can worsen these conditions. Thus ECMO is used to: Reduce ventilator pressure Prevent further lung damage Allow lung healing. 5. Ventilator Strategy: Minimize Positive Pressure Typical strategy: Rapid ECMO initiation if ventilation causes lung injury Attempt early extubation If needed: tracheostomy minimal ventilator settings Example “rest settings” described: Driving pressure ≈ 10 PEEP ≈ 10 (often reduced further) FiO₂ ≈ 50% Goal: avoid further lung trauma. 6. ECMO Candidate Selection Primary question: Is the disease reversible? If yes → ECMO should be considered. Factors supporting ECMO: Young patient Treatable infection Potential immune recovery Possible relative contraindications: Severe fungal infection Multiple uncontrolled opportunistic infections Extreme cachexia or severe systemic deterioration. 7. Early ART Should Be Started Modern approach: Start antiretroviral therapy during acute illness Do not delay until after ICU discharge Benefits: Rapid viral suppression Faster immune recovery Risk: Immune Reconstitution Inflammatory Syndrome (IRIS) Temporary worsening of infection due to immune rebound. 8. Circuit and Infection Complications Important ECMO considerations in HIV patients: Increased risk of circuit thrombosis Possible fungemia If fungemia occurs: circuit replacement possible re-cannulation These complications require careful monitoring. 9. Cannulation Strategy Example high-volume center approach: Bilateral femoral VV ECMO cannulation Fast Reliable flow Allows later neck access if needed Used especially during high-volume periods (e.g., COVID). 10. Outcomes and Indication Expansion ECMO indications are evolving: Older age Longer ventilator times HIV/AIDS Cancer patients All are examples of “indication creep” as experience grows. The key principle remains: ECMO should be used if there is a realistic chance of recovery. 11. Resource and Program Considerations Decision-making must consider: Resource availability Program experience Institutional risk tolerance High-volume ECMO centers can often accept higher-risk patients. 12. Broader Lesson Medical contraindications often change with new technology and therapies. Example given: HIV was once a contraindication for kidney transplantation Now it is accepted due to improved treatment. The same evolution may be happening with ECMO indications.

    57 min
  2. 07/29/2025

    EDECMO 98: Eddy Fan – VV ECMO – Numbers, Nuance, and the Human Factor

    Who Really Gets VV ECMO? Numbers, Nuance, and the Human Factor Is VV ECMO purely a numbers game? Or is there a softer, more human side to deciding who receives this life-saving therapy? In this candid and insightful interview, Jon Marinaro sits down with the legendary Dr. Eddy Fan—one of the most published and respected voices in the field of critical care. Together, they unpack the hard data and the gray areas: prognostic scoring, patient selection, and the ethical dilemmas that come with scarce resources. They also dive into the “sticky” dynamics of ECMO programs, including the subtle (or not-so-subtle) influence that a cannulating specialist can have on who actually gets the therapy. This is a must-listen for anyone working at the intersection of critical care, ethics, and real-world ECMO decision-making. Rubin J, Witkin AS, Crowley JC, Michel E, Furfaro DM, Teijeiro-Paradis R, Ilg A, Seethala R, Zhao S, Fan E. Venovenous Extracorporeal Membrane Oxygenation Candidacy Decision-Making: Lessons and Hypotheses From a Single-Center Observational Analysis. Chest. 2024 Sep;166(3):491-501. doi: 10.1016/j.chest.2024.02.042. Epub 2024 Feb 27. PMID: 38423278. Combes A, Schmidt M, Hodgson CL, Fan E, Ferguson ND, Fraser JF, Jaber S, Pesenti A, Ranieri M, Rowan K, Shekar K, Slutsky AS, Brodie D. Extracorporeal life support for adults with acute respiratory distress syndrome. Intensive Care Med. 2020 Dec;46(12):2464-2476. doi: 10.1007/s00134-020-06290-1. Epub 2020 Nov 2. PMID: 33140180; PMCID: PMC7605473.

    45 min
4.6
out of 5
88 Ratings

About

The ED ECMO Project is the work of Zack Shinar and Jon Marinaro to bring extracorporeal life support to EDs and ICUs around the world. This site aims to be the ultimate resource for the background, logistics, and evidence for resuscitative ECMO.

You Might Also Like